
    
      Pediatric heart transplant recipients receiving MMF will undergo study testing to measure MPA
      levels by the HPLC method and T-cell subsets by flow cytometry method. As standard of care
      they receive histological grading of routine endomyocardial biopsies using the International
      Society of Heart Lung Transplantation (ISHLT) grading scale. The data obtained from standard
      assessments will include medications, echocardiographic reports, pre-and post biopsy
      assessments/physical exams, hospital records for any inpatient hospitalization, and any
      laboratory assessments. Also, information will be collected on all patients which will be
      examined for tolerance and success (side effects and rejection) of immunosuppressive therapy.

      In newly transplanted patients, study testing will occur at the same time as standard of care
      biopsies which are typically 1 week, 2 weeks, 3 weeks, 4 weeks, 6 weeks, 8 weeks, 3 months, 4
      months, 5 months, 6 months, 8 months, 10 months, 12 months. If the patient has additional
      visits due to rejection or changes in immunosuppression, then more frequent study testing may
      be done per investigator preference. Previously transplanted patients will have study testing
      at the same time as their standard of care visits, usually annually.
    
  